Safety Issue Halts Study of BMS HCV Drug
10:24 EDT 2 Aug 2012 | MedPageToday
(MedPage Today) -- Bristol-Myers Squibb has suspended treatment "to protect patient safety" in a phase IIb trial of an investigational oral drug for hepatitis C.
Original Article: Safety Issue Halts Study of BMS HCV Drug
More From BioPortfolio on "Safety Issue Halts Study of BMS HCV Drug"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
